Pfizer accelerates Crizotinib regulatory procedures – Pharmaceutical Business Review

by lowes1 on May 20, 2011


InPharm
Pfizer accelerates Crizotinib regulatory procedures
Pharmaceutical Business Review
Pfizer has received the US Food and Drug Adminstration's (FDA) acceptance for filing new drug application (NDA) for Crizotinib as a treatment for the patients who are suffering from ALK-positive advanced non-small cell lung cancer (NSCLC).
Pfizer Lung Cancer Drug to Get Priority ReviewXconomy
FDA Grants Pfizer Priority Review For Lung Cancer DrugMyStateline.com
Pfizer lung cancer drug – Is FDA becoming more Open to Experimental Therapies?Gerson Lehrman Group
Investor’s Business Daily -WKZO -Pharma Times
all 78 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: